POMT2

Migration, Crosslink

📖

POMT2

active

wiki page Created: 2026-04-02T07:19:17 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-pomt2

📖 Wiki Page

gene1745 wordssynced 2026-04-02

POMT2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">POMT2</th>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Function</td>
</tr>
<tr>
<td class="label">α-Dystroglycan</td>
<td>ECM receptor</td>
</tr>
<tr>
<td class="label">Contactin-1</td>
<td>Neural adhesion</td>
</tr>
<tr>
<td class="label">Neuroglycan-C</td>
<td>Neural development</td>
</tr>
<tr>
<td class="label">Receptor-type protein tyrosine phosphatases</td>
<td>Cell signaling</td>
</tr>
<tr>
<td class="label">System</td>
<td>Manifestation</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>Severe hypotonia, weakness</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Cobblestone lissencephaly, cerebellar hypoplasia</td>
</tr>
<tr>
<td class="label">Eye</td>
<td>Retinal dysplasia, cataracts, microphthalmia</td>
</tr>
<tr>
<td class="label">Development</td>
<td>Profound intellectual disability</td>
</tr>
<tr>
<td class="label">Survival</td>
<td>Often fatal in infancy</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Cardiac muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Peripheral nerve</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>Moderate</td>
</tr>
<tr>
<

...

POMT2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">POMT2</th>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Function</td>
</tr>
<tr>
<td class="label">α-Dystroglycan</td>
<td>ECM receptor</td>
</tr>
<tr>
<td class="label">Contactin-1</td>
<td>Neural adhesion</td>
</tr>
<tr>
<td class="label">Neuroglycan-C</td>
<td>Neural development</td>
</tr>
<tr>
<td class="label">Receptor-type protein tyrosine phosphatases</td>
<td>Cell signaling</td>
</tr>
<tr>
<td class="label">System</td>
<td>Manifestation</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>Severe hypotonia, weakness</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Cobblestone lissencephaly, cerebellar hypoplasia</td>
</tr>
<tr>
<td class="label">Eye</td>
<td>Retinal dysplasia, cataracts, microphthalmia</td>
</tr>
<tr>
<td class="label">Development</td>
<td>Profound intellectual disability</td>
</tr>
<tr>
<td class="label">Survival</td>
<td>Often fatal in infancy</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Cardiac muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Peripheral nerve</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated POMT2 delivery</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Enzyme activity enhancement</td>
</tr>
<tr>
<td class="label">Substrate supplementation</td>
<td>Mannose analogs</td>
</tr>
<tr>
<td class="label">Gene editing</td>
<td>CRISPR-Cas9 correction</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant α-DG</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">POMT1</td>
<td>Heterodimer</td>
</tr>
<tr>
<td class="label">DPM1</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">DPM2</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">DPM3</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">DAG1</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">CALR</td>
<td>Chaperone</td>
</tr>
<tr>
<td class="label">HSPA5</td>
<td>Chaperone</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

POMT2 (Protein O-Mannosyltransferase 2) is an endoplasmic reticulum-resident glycosyltransferase that catalyzes the critical first step in the O-mannosylation of proteins. Located on chromosome 14q24.3 with NCBI Gene ID 29954, POMT2 operates as part of a functional heterodimeric complex with POMT1 to transfer mannose from dolichol-phosphate-mannose to serine and threonine residues on target proteins[@Akasaka2006]. This post-translational modification is essential for the functional maturation of alpha-dystroglycan (α-DG), a key extracellular matrix (ECM) receptor that bridges the cytoskeleton to the extracellular environment in both muscle and neural tissues.

The clinical importance of POMT2 is underscored by the severe congenital muscular dystrophies caused by mutations in this gene, including Walker-Warburg syndrome (WWS) and Limb-Girdle muscular dystrophy type 2K (LGMD2K)[@Barone2015][@Godfrey2019]. These disorders exemplify the broader category of alpha-dystroglycanopathies, which represent a spectrum of diseases characterized by deficient O-mannosylation of α-DG. Beyond its well-established role in muscle disease, POMT2 has emerged as a crucial player in brain development and function, with implications for understanding neurodegenerative processes including Alzheimer's disease (AD) and Parkinson's disease (PD)[@Yoshida2017][@Chiyonobu2018].

Molecular Structure and Function

Enzyme Architecture

POMT2 is a type I transmembrane protein with a topology characteristic of the protein O-mannosyltransferase family. The protein consists of 650 amino acids and contains several functional domains:

N-terminal signal peptide: Directs ER targeting and translocation
Mannosyltransferase domain: The catalytic core located in the ER lumen
Multiple transmembrane helices: Anchor the protein in the ER membrane
C-terminal cytosolic tail: Contains potential trafficking signals

The catalytic mechanism involves:

Binding of dolichol-phosphate-mannose (DPM) as the mannose donor

Recognition of protein substrates bearing serine/threonine residues

Catalytic transfer of mannose to the hydroxyl group of the amino acid side chain

Release of the O-mannosylated product

The POMT1-POMT2 Complex

POMT2 functions exclusively as part of a heterodimeric complex with POMT1[@Uyama2012][@Inamori2012]. This partnership is essential because:

POMT1 lacks catalytic activity alone
POMT2 provides the catalytic site
The heterodimer achieves proper substrate recognition
Complex formation ensures correct ER localization
Cooperative interactions stabilize both proteins

The stoichiometry of the functional complex appears to involve multiple POMT1-POMT2 heterodimers forming higher-order oligomers that constitute the active enzyme complex.

Role in Protein O-Mannosylation

The O-Mannosylation Pathway

O-mannosylation represents a specialized form of glycosylation that is particularly important for a subset of proteins in vertebrates. The pathway involves several sequential enzymatic steps:

Mermaid diagram (expand to render)

Key Substrates

While O-mannosylation occurs on numerous proteins, α-dystroglycan (encoded by DAG1) represents the most biologically significant substrate:

Alpha-Dystroglycan Maturation

The O-mannosylation of α-DG is essential for its function as an ECM receptor[@Erick2014]. The maturation process involves:

Initial O-mannosylation: POMT1-POMT2 adds the first mannose

Phosphorylation: POMK adds phosphate to the C-2 position of mannose

Complex glycan addition: Additional sugars (GlcA, Xyl) are added

Functional protein: Mature α-DG can bind laminin, agrin, and perlecan

The final product is a highly specialized glycoconjugate that mediates critical cell-ECM interactions.

Role in the Nervous System

Neuronal Migration

During cortical development, POMT2-mediated O-mannosylation is essential for proper neuronal migration[@VanRee2016][@Yoshida2017]:

Radial glia interaction: Neurons use radial glia as guides during migration
α-DG function: Must be properly glycosylated to interact with ECM on radial glia
Laminin binding: ECM laminin on radial glia provides the migration pathway
Cellular consequences: Defective O-mannosylation leads to neuronal overmigration and cortical malformations

The mechanism involves:

Progenitor cells express α-DG with POMT2-dependent glycans

These glycans bind laminin in the glial limitans

This interaction enables proper adhesion during migration

Disruption leads to cobblestone lissencephaly

Axon Guidance and Circuit Formation

POMT2-dependent glycosylation affects multiple aspects of neural circuit development[@Hiejima2022]:

Axon pathfinding: Growing axons require α-DG for ECM interaction
Synapse formation: Postsynaptic specialization requires proper glycosylation
Myelination: Oligodendrocyte function depends on ECM interactions
Glial development: Bergmann glia require POMT2 for proper maturation

Neuroinflammation

Emerging evidence links POMT2 to neuroinflammatory processes:

Microglial activation: α-DG glycosylation affects inflammatory responses
Blood-brain barrier: ECM maintenance requires proper O-mannosylation
Reactive gliosis: Astrocyte responses may involve POMT2

Disease Associations

Walker-Warburg Syndrome

POMT2 mutations are among the most common causes of Walker-Warburg syndrome (WWS), a severe congenital muscular dystrophy with brain and eye malformations[@Barone2015][@Godfrey2019]. This represents the most severe end of the alpha-dystroglycanopathy spectrum.

Clinical Features:

Molecular Pathogenesis:

Null mutations: Complete loss of POMT2 function
Severe hypoglycosylation: α-DG cannot be glycosylated
No functional receptor: α-DG cannot bind laminin
ECM disconnection: Both muscle and brain affected

Genotype-Phenotype Correlations:

Missense mutations often retain partial function (milder phenotype)
Null alleles cause classic WWS
Compound heterozygosity influences severity

Limb-Girdle Muscular Dystrophy Type 2K

POMT2 mutations also cause LGMD2K, a milder form of muscular dystrophy[@Uyama2012][@Kawai2020]:

Onset: Childhood to early adulthood
Progression: Usually slow or non-progressive
Cardiac involvement: Typically not severe
Intellect: Usually preserved

The pathogenesis involves:

Residual activity: Mutations retain partial POMT2 function
Hypoglycosylation: α-DG has reduced but not absent function
Compensatory mechanisms: Some adaptation in milder cases

Alzheimer's Disease

POMT2 may be relevant to AD through several mechanisms[@Martin2021]:

Synaptic dysfunction: α-DG at synapses requires O-mannosylation

Extracellular matrix: ECM disruption affects neural circuits

Neuroinflammation: Altered inflammatory responses

Aβ processing: Possible interactions with APP metabolism

Parkinson's Disease

Connections between POMT2 and PD include:

Dopaminergic neuron function: α-DG supports neuronal survival

Axonal integrity: O-mannosylation maintains axonal health

Synaptic plasticity: Required for proper dopaminergic transmission

Glial function: Supporting neuron survival

Other Neurological Conditions

POMT2 dysfunction may contribute to:

Congenital muscular dystrophy with brain anomalies (MDC1B)
Fukuyama congenital muscular dystrophy (related gene)
Muscle-eye-brain disease (related gene)

Expression and Regulation

Tissue Distribution

POMT2 exhibits a broad but specific expression pattern:

Brain Regional Expression

Within the central nervous system:

Cerebral cortex: High in pyramidal neurons
Hippocampus: CA1-CA3 pyramidal cells, dentate granule cells
Cerebellum: Purkinje cells, granule cells
Subventricular zone: Neural progenitor cells
Olfactory bulb: Interneurons

Transcriptional Regulation

POMT2 expression is controlled by:

Developmental programs: High during embryogenesis

Tissue-specific factors: Muscle and neural transcription factors

Epigenetic regulation: DNA methylation patterns

Cellular stress: May be regulated under pathological conditions

Post-Translational Regulation

POMT2 activity is modulated by:

POMT1 interaction: Essential for catalytic activity
ER quality control: Chaperone-assisted folding
Protein stability: Turnover rates vary by tissue
Glycosylation state: Possible feedback regulation

Therapeutic Implications

Therapeutic Strategies

Targeting POMT2 or its pathway offers therapeutic opportunities:

Challenges

Therapeutic development faces several obstacles:

ER delivery: Targeting the correct cellular compartment
Blood-brain barrier: CNS delivery is challenging
Immune response: Immune reactions to overexpressed protein
Dosage: Achieving therapeutic levels without toxicity

Biomarkers

POMT2-related biomarkers include:

Enzyme activity: Assessed in patient fibroblasts
α-DG glycosylation: Detected by specific antibodies
Genetic testing: Mutation identification
Serum biomarkers: Creatine kinase levels

Interaction Network

The O-Mannosylation Machinery

POMT2 interacts with multiple proteins in the glycosylation pathway:

Downstream Effectors

The functional consequences of POMT2 activity extend through:

ECM proteins: Laminin, agrin, perlecan
Integrin receptors: Alternative adhesion pathways
Cytoskeletal proteins: Dystrophin, syntrophins
Signaling molecules: FAK, Src family kinases

Research Directions

Unresolved Questions

Key questions about POMT2 remain:

Complete substrate repertoire: What other proteins are O-mannosylated?

Neuronal mechanisms: How exactly does O-mannosylation affect cognition?

Therapeutic delivery: Best approaches for CNS delivery?

Biomarkers: Predictive markers for disease progression?

Emerging Research Areas

Cryo-EM structures: Resolving the enzyme complex at high resolution
iPSC models: Patient-derived neurons for disease modeling
Single-cell analysis: Understanding cell-type specific functions
Proteomics: Mapping O-mannosylation across tissues

External Links

[Ensembl: ENSG00000044090](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000044090)
[UniProt: Q8N5L2](https://www.uniprot.org/uniprot/Q8N5L2)
[GeneCards: POMT2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=POMT2)
[OMIM: 607352](https://www.omim.org/entry/607352)
[NCBI Gene: 29954](https://www.ncbi.nlm.nih.gov/gene/29954)

References

[Akasaka-Manya et al., POMT1 and POMT2 are required for O-mannosylation (2006)](https://pubmed.ncbi.nlm.nih.gov/16672240/)

[Uyama & Endo, POMT1 and POMT2: novel therapeutic targets (2012)](https://pubmed.ncbi.nlm.nih.gov/22573681/)

[Erick & Martin, Alpha-dystroglycan O-mannosylation and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24751964/)

[Barone et al., POMT2-related muscular dystrophy phenotype (2015)](https://pubmed.ncbi.nlm.nih.gov/25644156/)

[Van Ree et al., POMT2 required for neuronal migration (2016)](https://pubmed.ncbi.nlm.nih.gov/27268856/)

[Yoshida et al., O-mannosylation and brain development (2017)](https://pubmed.ncbi.nlm.nih.gov/28627145/)

[Chiyonobu et al., POMT2 and glycosylation in CNS (2018)](https://pubmed.ncbi.nlm.nih.gov/29850896/)

[Godfrey et al., POMT2-related muscular dystrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/31153908/)

[Kawai et al., POMT2 and alpha-dystroglycanopathy (2020)](https://pubmed.ncbi.nlm.nih.gov/32278454/)

[Martin et al., O-mannosylation in neuronal function (2021)](https://pubmed.ncbi.nlm.nih.gov/33252859/)

[Hiejima et al., POMT2 and neural circuit formation (2022)](https://pubmed.ncbi.nlm.nih.gov/34791645/)

[Inamori et al., POMT1 and POMT2 function and therapeutic implications (2012)](https://doi.org/10.1007/s00415-012-6541-7)

📖 View canonical wiki page →

Related Entities

POMT2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-pomt2
kg_node_id	POMT2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-02c7f1f1df16
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-pomt2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

POMT2

POMT2

Overview

POMT2

Overview

Molecular Structure and Function

Enzyme Architecture

The POMT1-POMT2 Complex

Role in Protein O-Mannosylation

The O-Mannosylation Pathway

Key Substrates

Alpha-Dystroglycan Maturation

Role in the Nervous System

Neuronal Migration

Axon Guidance and Circuit Formation

Neuroinflammation

Disease Associations

Walker-Warburg Syndrome

Limb-Girdle Muscular Dystrophy Type 2K

Alzheimer's Disease

Parkinson's Disease

Other Neurological Conditions

Expression and Regulation

Tissue Distribution

Brain Regional Expression

Transcriptional Regulation

Post-Translational Regulation

Therapeutic Implications

Therapeutic Strategies

Challenges

Biomarkers

Interaction Network

The O-Mannosylation Machinery

Downstream Effectors

Research Directions

Unresolved Questions

Emerging Research Areas

See Also

External Links

References

💬 Discussion